Divi's Laboratories Limited (NSE:DIVISLAB)

India flag India · Delayed Price · Currency is INR
6,620.00
-16.00 (-0.24%)
May 29, 2025, 3:29 PM IST
50.73%
Market Cap 1.76T
Revenue (ttm) 93.60B
Net Income (ttm) 21.91B
Shares Out 265.47M
EPS (ttm) 82.53
PE Ratio 80.35
Forward PE 65.37
Dividend 30.00 (0.45%)
Ex-Dividend Date Jul 25, 2025
Volume 364,734
Average Volume 632,063
Open 6,645.00
Previous Close 6,636.00
Day's Range 6,603.00 - 6,670.50
52-Week Range 4,180.50 - 6,764.00
Beta 0.28
RSI 64.51
Earnings Date May 23, 2025

About Divi's Laboratories

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It al... [Read more]

Sector Healthcare
Founded 1990
Employees 9,741
Stock Exchange National Stock Exchange of India
Ticker Symbol DIVISLAB
Full Company Profile

Financial Performance

In 2024, Divi's Laboratories's revenue was 93.60 billion, an increase of 19.31% compared to the previous year's 78.45 billion. Earnings were 21.91 billion, an increase of 36.94%.

Financial Statements

News

Morgan Stanley maintains overweight on Divis Labs, sees 11% upside after second global order win

Morgan Stanley has maintained its Overweight rating on Divis Laboratories, with a target price of ₹7,185, implying a 10.8% upside from the current market price of ₹6,482.50. The call comes after Divis...

3 days ago - Business Upturn

Divis Laboratories signs long-term supply deal with global pharma company

Divis Laboratories has recently informed exchanges that the company entered into a long-term manufacturing and supply agreement with a global pharmaceutical company. This international agreement marks...

5 days ago - Business Upturn

BHEL, Hyundai & more: Top stocks on brokers' radar today

Equirus downgraded Protean eGovernance due to losing a key government project, impacting revenue significantly. Jefferies maintains a hold on Divis Laboratories, citing patent challenges and valuation...

9 days ago - The Times of India

Stocks in news today: Divis Labs, Delhivery, Premier Energies, Zen Tech, KRBL, Galaxy Surfactants, Kaynes Tech after Q4 earnings on May 19

A series of Q4 earnings results released across sectors have highlighted key performers and corporate actions that could drive market sentiment. Here are the major updates from the companies that anno...

10 days ago - Business Upturn

Divi's Laboratories Ltd (BOM:532488) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ...

Divi's Laboratories Ltd (BOM:532488) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions

3 months ago - GuruFocus

Q3 2025 Divi's Laboratories Ltd Earnings Call Transcript

Q3 2025 Divi's Laboratories Ltd Earnings Call Transcript

3 months ago - GuruFocus

Divi’s Labs remains our top pick, target price at Rs 6,850 after Q3 results: Citi

Citi has reaffirmed its 'Buy' rating on Divi's Laboratories, maintaining it as a top pick with a target price of Rs 6850, following a robust Q3 performance.

4 months ago - Business Upturn

Citi reaffirms ‘Buy’ on Divi’s Laboratories, sees buying opportunities amid BioSecure delays

Citi has reiterated its "Buy" rating on Divi's Laboratories with a target price of ₹6,850, emphasizing the company’s strong growth pipeline despite delays in the BioSecure Act.

6 months ago - Business Upturn

Divi's Laboratories Ltd (BOM:532488) Q2 2025 Earnings Call Highlights: Navigating Growth Amidst ...

Divi's Laboratories Ltd (BOM:532488) Q2 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges

7 months ago - GuruFocus

Q2 2025 Divi's Laboratories Ltd Earnings Call Transcript

Q2 2025 Divi's Laboratories Ltd Earnings Call Transcript

7 months ago - GuruFocus

Divis Labs surges over 4.5% on positive brokerage report

Divis Laboratories Limited (NSE: DIVISLAB) saw a notable rise in its stock price, gaining ₹250.85 (+4.52%) to trade at ₹5,797.90 as of 9:26 AM. The stock opened at ₹5,655.90 and reached a high of ₹5,8...

8 months ago - Business Upturn

Citi initiates Buy on Divis Lab, sees 15% upside in share price

Citi has initiated a ‘Buy’ rating on Divis Laboratories with a target price of ₹6,400, representing a 15% upside from the current market price of ₹5,555.55. The brokerage highlights Divis Lab’s strong...

8 months ago - Business Upturn

Stock Market Today: Top gainers and losers in market today, September 10, 2024; Divis Labs, LTIMindtree, HDFC Life Insurance and more

The stock market closed positively on September 10, with the Sensex gaining 362 points and the Nifty staying above 25,000. IT, media, and telecom sectors led the rally, while oil and gas remained the ...

9 months ago - Business Upturn